Status:
UNKNOWN
Study of Chemotherapy Plus Icotinib to Treat EGFR Mutation-positive Non-small-cell Lung Cancer
Lead Sponsor:
Nanfang Hospital, Southern Medical University
Conditions:
NSCLC
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Non-small-cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutations are exquisitely sensitive to epidermal growth factor receptor tyrosine kinase inhibitors (...
Eligibility Criteria
Inclusion
- Patients undergoing completely resection of EGRF mutation-positive NSCLC
- Staging ⅠB (with high risk factor) to ⅢA
- PS\<2
- Adequate hematological, biochemical and organ functions.
Exclusion
- Systemic anticancer therapy prior to surgery, other malignancies before or during the study, any unstable illness, women who were pregnant or lactating.
Key Trial Info
Start Date :
July 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2019
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT02272127
Start Date
July 1 2014
End Date
July 1 2019
Last Update
October 22 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong, China, 510515